Pliant Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Pliant Therapeutics, Inc. carries a market capitalization of 71.83M, placing it among publicly traded companies globally. Its enterprise value stands at -64.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 71.83M |
| Enterprise Value | -64.60M |
Share Statistics
Pliant Therapeutics, Inc. currently has 61.91M shares outstanding.
| Shares Outstanding | 61.91M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.09 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | -0.79 |
| P/OCF Ratio | -0.79 |
Financial Position
Pliant Therapeutics, Inc. maintains a current ratio of 16.89, meaning it holds 16.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.43, indicating elevated leverage, while an interest coverage ratio of -66.87 demonstrates limited ability to service its debt obligations.
| Current Ratio | 16.89 |
| Quick Ratio | 16.59 |
| Debt / Equity | 17.43 |
| Debt / EBITDA | -0.24 |
| Interest Coverage | -66.87 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -41.37 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Pliant Therapeutics, Inc.'s stock has declined approximately -27.5% over the past 52 weeks. The 50-day moving average sits at 1.24, while the 200-day moving average is 1.38.
| Beta (5Y) | N/A |
| 52-Week Price Change | -27.5% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.38 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -117.70M, while operating income came in at -119.21M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -119.21M |
| Pretax Income | -113.22M |
| Net Income | -113.22M |
| EBITDA | -117.70M |
| EBIT | -119.21M |
| Earnings Per Share (EPS) | -1.84 |
Balance Sheet
Pliant Therapeutics, Inc. holds 170.89M in cash and equivalents against 28.78M in total debt, resulting in a net debt position of -22.19M. Total book value stands at -879.43M, with working capital of 164.57M providing operational flexibility.
| Cash & Cash Equivalents | 170.89M |
| Total Debt | 28.78M |
| Net Debt | -22.19M |
| Equity (Book Value) | -879.43M |
| Book Value Per Share | -14.30 |
| Working Capital | 164.57M |
Cash Flow
Pliant Therapeutics, Inc. produced -98.70M in operating cash flow over the past twelve months. After subtracting -112,000.00 in capital expenditures, free cash flow totaled -98.81M - equivalent to -1.61 per share.
| Operating Cash Flow | -98.70M |
| Capital Expenditures | -112,000.00 |
| Free Cash Flow | -98.81M |
| FCF Per Share | -1.61 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 41.44 |
| FCF Yield | -127.20 |
Scores
Pliant Therapeutics, Inc. posts an Altman Z-Score of -5.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.80 |